Bevacizumab Alone Effective for Recurrent Glioblastoma
the Cancer Therapy Advisor take:
Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma, according to a recent study published in Medical Oncology.
Researchers led by Ilhan Hacibekiroglu of Trakya University in Turkey observed 22 patients with glioblastoma and two patients with World Health Organization III glioma who had been previously treated with temozolomide with radiotherapy and received 10mg/kg bevacizumab intravenously every two weeks until disease progression.
The researchers found that the performance status of 17 patients (70.8 percent) was improved with the bevacizumab regimen. Upon univariate analysis, performance status following bevacizumab therapy was found to be a significant predictor of both progression-free survival (PFS) and overall survival (OS).
In addition, overall response rate was 20.8 percent, with median OS at 6.4 months. Six-month PFS was 37.5 percent and median PFS was 4.1 months.
Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
- Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count
- Expert Panel Provides Recommendations for Running Trials on Intratumoral Immunotherapy
- Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments
- Treatment of H. pylori Increased Platelet Count in ITP
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD